What is Cyclacel Pharmaceuticals, Inc. (CYCC)?

Cyclacel Pharmaceuticals, Inc. (CYCC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CYCC?

The current price of CYCC is $6.37. Prices are updated in real time on Stocks360.

What is CYCC's price-to-earnings (PE) ratio?

CYCC's trailing twelve-month PE ratio is -3.08, based on current price and earnings per share data available on Stocks360.

What is CYCC's market capitalization?

CYCC's market capitalization is $10,608,329.00, placing it in the small-cap tier.

Cyclacel Pharmaceuticals, Inc. (CYCC)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$6.37

Market Cap

$10.61M

PE (TTM)

-3.08

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.16

Day Range

$6.10 – $6.96

52-wk Range

$3.08 – $597.60

Avg Volume

N/A

Volume

219.91K

Cyclacel Pharmaceuticals, Inc. (CYCC) is a publicly traded company in the Healthcare sector. Latest price: $6.37. Market cap $10.61M. Trailing PE -3.08. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

Earnings

Most Recent

Nov 13, 2025

EPS $-0.00 vs est. $-72.00

Beat by $72.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies. CYC140, a polo-like kinase inhibitor, has progressed to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies. Sapacitabine, an innovative orally available nucleoside analog (a prodrug of CNDAC), is also in Phase 1/2 clinical trials, targeting acute myeloid leukemia and myelodysplastic syndrome. The pipeline further features Seliciclib, another CDK inhibitor, which is being investigated in investigator-sponsored trials (ISTs), including a Phase 2 study for Cushing's disease and a Phase 1/2 study for advanced rheumatoid arthritis. In a key strategic alliance, Cyclacel h…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-3.08×
P/S (TTM)	6.95×
P/B	4.98×
P/FCF (TTM)	-1.97×
EV / EBITDA	-28.36×
EV / Sales	4.47×
Earnings Yield	-5.04%
Free Cash Flow Yield	-50.87%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$6.82M
Revenue (TTM)	$1.53M
Net Income (TTM)	-$534.77K
Free Cash Flow (TTM)	-$5.40M
Net Debt	-$3.79M
Working Capital	$5.28M
Gross Margin	18.36%
Operating Margin	-178.65%
Net Margin	-117.77%
Return on Equity	-34.60%
Return on Invested Capital	-38.05%